CD274 and neoplasm: In addition to the use of PD-L1 IHC and tumour mutational burden (TMB), the authors analysed the algorithmic response score (RS) and assessed how this parameter, being a continuous variable, could better serve as a decision support for the clinician; in fact, immune profiling with RS showed a higher sensitivity (72.2%) than PD-L1 IHC and TMB (32.5%) albeit with a similar specificity.